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ABSTRACT OF THE THESIS 
Tests, Tests, and More Tests: A New Era for Dementia Diagnosis 
by  
Jonathan Gooblar 
Master of Arts in Psychology 
Washington University in St. Louis, 2013 
Professor Brian D. Carpenter, Chair 
 Cerebrospinal fluid (CSF) proteins correlate with pathological changes that are hallmarks 
of Alzheimer’s disease (AD). CSF biomarkers have been used in research settings to predict AD 
diagnosis and rate of cognitive decline, however their use in clinical settings is limited. Given 
their potential utility in identifying preclinical AD and in increasing diagnostic confidence in 
clinical settings, we sought to understand how clinicians use CSF biomarkers in conjunction with 
other clinical details to diagnose AD. Participants (N = 193) were physicians and other medical 
professionals who routinely evaluate older adults for neurodegenerative disease. In a within-
subjects factorial design, participants were randomized and viewed normal, borderline, AD-
consistent, or no CSF information along with two clinical vignettes portraying patients with 
borderline and mild AD symptoms. In addition, clinicians reported on their use and the utility of 
CSF lab results in clinical practice. Clinicians reported infrequent use and limited utility of CSF 
biomarkers in clinical practice, yet CSF biomarkers affected clinical decisions on two vignettes. 
AD-consistent CSF values made clinicians 6-12 times more likely to make an AD-related 
diagnosis, increased diagnostic confidence, and led clinicians to initiate treatment more often 
than other CSF values. Furthermore, clinicians relied on CSF evidence more heavily when AD-
consistent CSF values were presented in the context of a borderline case of memory impairment. 
 vi 
In sum, CSF biomarkers have a significant impact on clinical decisions, and show different 
effects depending on contextual factors. Therefore, as CSF biomarkers become more widespread 
in clinical practice, clinicians should consider the potentially significant effect of biomarkers on 
their clinical decisions. 
 
 1 
Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the United States, 
and if left untreated is expected to affect nearly 14 million people by the year 2050 (Hebert, 
Weuve, Scherr, & Evans, 2013). AD is widely conceptualized as a clinical and pathological 
process, encompassing memory impairment and functional decline as well as brain changes such 
as neurofibrillary tangles and amyloid plaques (Dubois et al., 2010). Clinical tools commonly 
used to assess patients with memory complaints who may have AD range from 
neuropsychological testing and functional assessments to laboratory blood analysis and 
neuroimaging. Increasingly, cerebrospinal fluid (CSF) biomarkers shown to correlate with AD 
pathological changes have been used in research settings to evaluate cases of suspected incipient 
AD, discriminate among different etiologies, predict rate of disease progression, and track 
pathological changes in clinical trials (Blennow, 2005; Snider et al., 2009; Toledo et al., 2012). 
However, recent practice guidelines have not endorsed the use of CSF biomarkers in clinical 
settings, citing the need for further research on laboratory standardization of biomarker 
measurements and interpretation of indeterminate biomarker results (McKhann et al., 2011). 
Furthermore, it is unclear how clinicians would interpret CSF information in conjunction with 
other clinical details in clinical practice (Zetterberg, Lunn, & Herukka, 2012). As CSF 
biomarkers become more widespread in clinical practice, we sought to evaluate their influence 
on clinical dementia evaluations and to understand how clinicians interpret CSF information in 
various clinical contexts. In this study, we employed a vignette-based survey with clinicians who 
evaluate older adults to examine the impact of CSF biomarker information on diagnostic 
decisions, diagnostic confidence, and treatment choices for two hypothetical patients with 
memory complaints.  
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The role of CSF information in clinical dementia assessment is evolving. While CSF 
biomarkers are widely used in research settings and have shown good predictive ability for AD 
diagnosis, their use in clinical settings is limited (Blennow & Zetterberg, 2009). Concerns about 
laboratory standardization and potential for conflicting or ambiguous CSF values have kept 
biomarker tests from widespread clinical use (McKhann et al., 2011). Furthermore, the 
possibility of identifying pathological processes in clinically normal individuals raises ethical 
issues given a lack of meaningful treatment options for dementia. Yet, CSF biomarkers could 
play an important role in clarifying ambiguous cases, discriminating among the dementias, and 
predicting progression of cognitive impairment and dementia (Snider et al., 2009; Tabaraud et 
al., 2012; Zetterberg et al., 2012). A recent study addressing concerns about unreliable cross-
laboratory measurements concluded that locally standardized procedures could increase the 
reliability and usefulness CSF measures (Mattson et al., 2012). Importantly, early reliable 
diagnosis of AD could be necessary for preventative treatment, and could give comfort to 
patients and families who are eager to understand possible causes of cognitive decline. 
It remains unknown, however, how clinicians might use CSF biomarker information in 
clinical practice. Previous studies have examined the utility of CSF information in research 
settings, finding good diagnostic sensitivity and correlation with pathological markers of AD 
progression such as structural brain changes (Blennow, 2005; Fagan et al., 2009). Other studies 
have supported the utility of CSF biomarkers in identifying AD pathology in preclinical and MCI 
populations, and in older adults with suspected AD (Mattson et al., 2012; Parnetti, Lanari, 
Silvestrelli, Saggese, & Reboldi, 2006; Stomrud, Hansson, Blennow, Minthon, & Londos, 2007). 
No research to our knowledge, however, has surveyed clinicians to examine how CSF 
information might be used in conjunction with other clinical details to diagnose dementia. 
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Furthermore, no previous studies to our knowledge have evaluated the utility of CSF biomarkers 
in combination with other clinical details in evaluating patients with memory complaints.   
In this study, we presented clinicians with two clinical vignettes to illustrate a typical 
ambiguous and mild-AD presentation in a clinic or hospital. Clinical vignettes are a valuable, 
cost-effective research method for understanding professional judgment of multiple clinical 
factors while mirroring plausible real-world scenarios (Veloski, Tai, Evans, & Nash, 2005). 
Clinicians, including physicians, nurse practitioners, physician assistants, and advanced practice 
nurses, were randomized into one of four groups according to the type of CSF biomarker 
information they viewed. Three of the groups viewed CSF values consistent with normal, 
borderline, or AD patient presentations, while the fourth group did not view any CSF 
information embedded in the vignettes. Given previous studies about the utility of CSF 
information in research settings, we hypothesized that biomarker values would influence 
diagnosis, diagnostic confidence, and treatment planning. In addition, we assessed demographic 
factors, clinician use of and confidence in clinical tools for assessing patients with memory 
impairment, and clinician evaluation of clinical details in the vignettes. 
 
Method 
Participants 
Recruitment. Physicians (MD and DO), nurse practitioners and advanced practice nurses 
(NP and APRN), and physician assistants (PA) were eligible for the study if they routinely 
evaluate patients over age 65. We targeted academic and nonacademic clinicians and recruited 
from primary care, internal medicine, neurology, geriatrics, and geriatric psychiatry. Potential 
participants were contacted using publicly available e-mail addresses on university and medical 
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center websites and professional organization e-mail lists and public contact information. 
Between January and July, 2013, we distributed recruitment e-mails describing the scope of the 
study and including a link to the questionnaire, which was hosted by Qualtrics, a secure online 
survey platform. Informed consent was obtained from all participants in the study, which was 
approved by the Washington University Human Research Protection Office.  
Sample size. Based on a desired power of .8, alpha set at .05, and a conventional medium 
effect size, G*Power suggested a required sample size of 192 to perform chi-square analyses 
(Cohen, 1988; Faul, Erdfelder, Lang, & Buchner, 2009). Out of 291 individuals who began the 
questionnaire, 248 respondents were eligible to participate and were randomized into conditions 
in the study. A total of 193 participants completed the entire questionnaire, while 55 partially 
completed the questionnaire. Completers and partial completers were statistically similar in 
terms of age, years in clinical practice, approximate percentage of patients seen over the age of 
65, practice specialty, and practice setting.  
Materials 
The study design and materials (details below) were developed by a team of investigators 
representing neurology, nursing, clinical psychology, and social work. We pilot tested the 
questionnaire with 10 clinicians at the Knight Alzheimer’s Disease Research Center and revised 
it for clarity based on their feedback. The questionnaire included demographic and clinical 
practice questions, one page of education materials about CSF biomarkers for diagnosing AD, 
and two clinical vignettes with follow-up diagnostic questions. 
Demographic and practice questions and randomization. At the start of the 
questionnaire, participants completed a series of demographic and professional background 
questions. If they met inclusion criteria, participants were randomized into one of four 
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experimental groups according to the type of CSF information they viewed with each of two 
clinical vignettes, consistent with a 2 x 4 within-subjects factorial design. Participants in groups 
1, 2, and 3 were shown normal, borderline, or AD-consistent CSF values, respectively, with each 
vignette, while participants in group 4 were not shown any CSF information. After 
randomization, participants responded to clinical practice questions (i.e., how often they collect, 
and how useful they find, various diagnostic tests for cognitive impairment). Figure 1 outlines 
randomization and procedural flow.  
CSF education. We developed a one-page education sheet outlining the clinical use of 
CSF biomarkers in identifying AD pathology (see Appendix A). This information was presented 
directly before the two clinical vignettes and contained sensitivity and specificity information for 
Aβ42, ttau, ptau, and the ratio between Aβ42 and ttau, which usually provides the best 
classification information for people with and without AD pathology (Fagan et al., 2007). The 
education sheet noted the limitations of these data due to overlap between diagnostic groups and 
the fact that CSF values indicate pathological, and not necessarily symptomatic, changes (Price 
et al., 2009; Price & Morris, 1999).  
Clinical vignettes. The two vignettes included information about age, gender, memory, 
functional status, mood, subjective complaints, and an informant report (see Appendix B). One 
vignette described a borderline or unclear case with ambiguous presenting symptoms, and the 
second described a patient with symptoms consistent with mild AD. Embedded in the vignettes 
were Aβ42, ttau, ptau, and ratio values consistent with each CSF condition (normal, borderline, or 
AD consistent), for participants randomized to receive CSF information. The order of the 
vignettes was counterbalanced across participants. 
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 After each vignette, participants chose a diagnosis from a list of six options (normal/no 
diagnosis, mild cognitive impairment (MCI) due to unknown causes, MCI due to AD, AD 
dementia, memory loss due to uncertain causes, or depression); rated their diagnostic confidence 
on a scale from 1 (not at all confident), 3 (moderately confident), to 5 (very confident); and 
indicated their recommendation for treatment, if any, in an open-ended response. Next, 
participants were asked whether each clinical detail in the vignette (i.e., age, gender, memory, 
functional status, mood, informant report, CSF values) made them less or more confident in their 
diagnosis on a 5-point Likert-type scale: 1 (less confident), 3 (neither less nor more confident), 5 
(more confident). Finally, participants were asked in an open-ended question what additional 
clinical details they would have liked in order to evaluate each vignette. While answering these 
questions, participants were able to view the relevant vignette and the CSF education page.  
Data analysis 
Statistical analyses were conducted in three phases using SPSS (version 21). First, 
descriptive statistics of demographic and practice information were calculated in order to 
examine sample characteristics. Second, chi-squares, t-tests, and analyses of variance were 
conducted in order to evaluate whether CSF information was related to diagnostic choices, 
diagnostic confidence, and treatment plan. Finally, a series of logistic regressions were 
conducted to model multivariate associations between clinician diagnosis and CSF group 
assignment, demographic and practice variables, and clinical detail ratings. 
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Results 
Demographic and practice information 
Table 1 summarizes demographic information for the sample. Respondents were mostly 
physicians (90%), although the non-MD clinicians did not differ from the physicians on any 
demographic or practice characteristics and were therefore included in the final sample to 
represent the diversity of clinicians evaluating and treating patients with neurodegenerative 
disease in the United States. Overall, participants reported a variety of practice specialties and 
were experienced in caring for older adults. 
 In terms of their practice behaviors, clinicians reported frequent use of cognitive 
screening tests and neuroimaging, moderate use of comprehensive cognitive testing, and 
infrequent use of metabolic and CSF tests (see Table 2). In terms of perceived utility, cognitive 
screening and comprehensive examinations were rated as very useful by most clinicians, whereas 
fewer respondents agreed on the utility of neuroimaging, and few clinicians rated metabolic or 
CSF testing as useful for diagnosing dementia. Significant differences were notable across 
practice specialties. Neurologists reported greater use of cognitive testing, neuroimaging, and 
lumbar puncture as compared to geriatricians and nonspecialists such as primary care and 
internal medicine clinicians. Neurologists also reported finding neuroimaging and lumbar 
puncture more useful than did nonspecialists and geriatricians.  
Does the presence of any type of CSF information influence clinical decisions? 
In order to examine the effect of CSF information on diagnostic decisions, we 
consolidated diagnostic categories from the questionnaire to eliminate small cell sizes and to 
reflect our interest in clinician choice of underlying etiology (AD-consistent or unknown 
etiology) rather than in diagnostic labels that may vary across practice specialty or setting. The 
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presence of CSF information was significantly related to diagnostic choices for the borderline 
vignette, χ2(1, N = 165) = 9.09, p = .003, but not for the AD vignette, χ2(1, N = 187) = 0.19, p = 
.67. Clinicians who received CSF information of any type were more likely to make an AD-
related diagnosis than clinicians who did not receive CSF information (47% compared to 22%; z 
= 3.0, p < .01).  
Diagnostic confidence ratings are detailed in Table 3. Clinicians who had CSF 
information with the AD vignette, but not the borderline vignette, rated their diagnostic 
confidence significantly higher than clinicians who did not have CSF information, t(191) = 2.83, 
p = .005. Furthermore, clinicians who chose an AD-related diagnosis on the AD vignette and had 
CSF information reported higher diagnostic confidence than clinicians who made the same 
diagnosis but did not have CSF information, t(96) = 2.03, p = .045. In other words, even when 
making a similar diagnosis with otherwise identical clinical information, clinicians reported 
higher diagnostic confidence when they had CSF information.  
Regarding treatment decisions, clinicians who had CSF information were more likely to 
suggest initiating treatment on the borderline vignette, χ2(1, N = 161) = 9.31, p = .002, but not on 
the AD vignette, χ2(1, N = 161) = 1.07, p = .30.  While most clinicians (70.8%) chose not to 
treat, those who had CSF information were more likely to initiate treatment (35.9%) in the 
borderline vignette compared to those who did not have CSF information (11.4% z = 3.1, p < 
.01). 
Do particular CSF protein values influence clinical decisions? 
Type of CSF information (normal, borderline, AD-consistent, or no CSF protein values) 
was related to clinician diagnosis for both the borderline and the AD vignette, as detailed in 
Figure 2. For both vignettes, the diagnosis chosen by clinicians depended, in part, on the CSF 
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values presented. When given normal CSF values, few clinicians made an AD-related diagnosis 
(19.4% for the borderline vignette, 27.3% for the AD vignette). The proportion of clinicians 
assigning a diagnosis related to AD was higher when they received borderline CSF values (41% 
for the borderline vignette, 47.7% for the AD vignette), and higher still when they received AD-
consistent CSF values (77.5% for the borderline vignette, 86% for the AD vignette). Clinicians 
who did not receive CSF information assigned diagnoses in equal numbers for the AD vignette, 
while most clinicians (78%) diagnosed unknown etiology for the borderline vignette. 
Regarding diagnostic confidence, there was a significant effect of CSF group on 
confidence ratings for both vignettes (for the borderline vignette, F(3,188) = 4.05, p = .008; for 
the AD vignette, F(3,189) = 5.66, p = .001). On the borderline vignette, clinicians who received 
AD-consistent CSF values were significantly more confident in their diagnosis compared to 
clinicians who did not view CSF information (see Table 3). On the AD vignette, clinicians who 
received AD-consistent CSF values were more confident in their diagnosis than clinicians who 
viewed borderline CSF values or no CSF information. In addition, clinicians who made an AD-
related diagnosis on the AD vignette and had AD-consistent information reported the highest 
diagnostic confidence compared to clinicians with borderline or no CSF information, F(3,94) = 
3.96, p = .01.  
There was a significant effect of CSF values on the decision to treat for the borderline 
vignette, χ2(3, N = 161) = 13.44, p = .004, but not for the AD vignette, χ2(3, N = 161) = 6.61, p = 
.086. Although most clinicians (70.8%) chose not to start treatment in the borderline vignette, 
clinicians who had AD-consistent CSF were significantly more likely to treat than those who had 
borderline or normal CSF values (48.5% versus 35% and 27.3%, respectively; z = 2.7, p < .01). 
On the AD vignette, adjusted residual scores indicated that clinicians receiving AD-consistent 
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CSF were more likely to initiate treatment than clinicians who received borderline or normal 
CSF values (58.8% versus 35.9% and 34.9%, respectively; z = 2.6, p < .01), although the 
omnibus chi-square test was not significant and this result should be interpreted with caution. 
Finally, a series of binary logistic regression models were evaluated to determine whether 
clinician demographic variables, CSF group assignment, and post-vignette responses predicted 
diagnostic choices (AD etiology versus unknown etiology; see Table 4). The most parsimonious 
models included CSF group as the only significant predictor variable for the borderline vignette, 
and CSF group and post-vignette confidence rating of the informant report as significant 
predictors of diagnosis on the AD vignette (see Table 4). For both vignettes, receiving AD-
consistent CSF values led to increased odds of choosing an AD-related diagnosis, while 
clinicians who rated the informant report as valuable in forming a diagnosis were more likely to 
choose an AD diagnosis on the AD vignette (but not the borderline vignette). Variables that were 
not significant predictors of diagnostic choices included demographic factors (years in practice, 
percentage of patients over age 65, and practice specialty), practice questions related to lumbar 
puncture use, and post-vignette clinical measure ratings (aside from informant report).  
Confidence ratings of clinical measures and preference for additional tests 
Following each vignette, participants rated whether clinical details that appeared in the 
vignette made them less or more confident in their diagnosis. Clinicians reported high diagnostic 
confidence ratings for collateral information from a family member and patient functional status, 
while patient age and CSF information were rated as least useful in formulating a diagnosis (see 
Table 5). In addition, post-vignette CSF ratings differed significantly from initial clinical practice 
questions. Clinicians rated CSF information included in the vignettes as significantly more useful 
compared to ratings of CSF biomarker utility in their clinical practice (for the borderline 
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vignette, M = 3.22 vs. 2.19, t(130) = 1.03, p < .001; for the AD vignette, M = 3.36 vs. 2.20, 
t(128) = 1.16, p < .001).  
Furthermore, post-vignette ratings of CSF utility depended in part on CSF group (for the 
borderline vignette, F(2, 132) = 5.99, p = .003; for the AD vignette, F(2, 130) = 8.37, p < .001). 
Tukey post-hoc tests showed that clinicians receiving AD-consistent CSF values on the 
borderline vignette rated CSF information as more useful than did clinicians who received 
borderline CSF values (M = 3.58 vs. M = 2.93). Clinicians who received AD-consistent CSF 
values on the AD vignette rated CSF information as more useful than did clinicians who received 
normal or borderline CSF values (M = 3.84 vs. normal CSF, M = 3.15 and vs. borderline CSF, M 
= 3.11). Taken together, these results indicate that while clinicians rated collateral reports and 
functional status as the most helpful clinical tools in formulating a diagnosis, viewing AD-
consistent CSF values provided a similar level of diagnostic confidence and they were rated as 
more helpful than borderline or normal CSF values.  
Finally, clinicians indicated which additional diagnostic tests they would have found 
useful in formulating a diagnosis in an open-ended response. For both vignettes, 25-30% of 
clinicians requested neuroimaging, neuropsychological testing, and laboratory information such 
as blood analysis. Fewer clinicians (approximately 15%) indicated that brief neuropsychological 
screening or a depression evaluation would have been useful. Clinicians also described a wide 
variety of additional information they would have collected. Some clinicians indicated that 
additional testing was required to arrive at a diagnosis (e.g., “Really must have cognitive testing 
as well.”). Others wrote that they would like longitudinal follow-up information as well as 
medical history. About 20% of participants requested one additional test, and another 20% each 
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requested two or three additional tests. Others (14% for the borderline vignette, 18% for the AD 
vignette) did not request any additional information.  
 
Discussion 
 This study is one of the first to examine how clinicians use CSF biomarkers in 
combination with other clinical information to diagnose cognitive impairment. Participants 
responded to practice questions and evaluated two vignettes describing patients with ambiguous 
borderline symptoms and with mild memory complaints. While clinicians reported infrequent 
use and limited utility of CSF biomarkers in their current clinical practice, the inclusion CSF 
information influenced diagnosis, diagnostic confidence, and the decision to treat. Taken 
together, these results highlight the influence of CSF biomarkers on clinical decisions, even 
when that information is weighed alongside other clinical details routinely reported as more 
useful in clinical practice. Examining these findings more closely, a number of trends are 
apparent. 
 First, results from this study suggest that holding CSF information makes clinicians more 
likely to assign an AD-related diagnosis, increases diagnostic confidence, and influences the 
decision to treat. Overall, clinicians who had CSF information of any type were more than twice 
as likely to make an AD-related diagnosis and were more likely to initiate treatment on a 
borderline case. In addition, clinicians who had CSF information reported significantly higher 
diagnostic confidence on a mild AD vignette. In sum, these results suggest that merely viewing 
CSF information of any type affects clinical decisions regardless of the particular protein values. 
It is notable that these effects were driven by clinicians who had borderline and AD-consistent 
CSF values, which could suggest that evaluating the impact of all three CSF groups together may 
not be meaningful. However, protein values are continuous measures, and therefore these effects 
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may apply to the virtually infinite combinations of CSF protein values clinicians are likely to 
encounter in clinical practice.  
Second, as CSF values increasingly reflected AD pathology, clinicians made AD-related 
diagnoses with increasing frequency and with greater confidence (see Figure 2). Clinicians who 
viewed normal CSF values disproportionately made diagnoses with unknown etiology, while 
most clinicians who viewed AD-consistent CSF values made AD-related diagnoses. 
Furthermore, the proportion of clinicians choosing to initiate treatment on the borderline vignette 
rose as CSF values increasingly pointed to AD pathology (27.3%, 35%, and 48.5% for normal, 
borderline, and AD CSF values, respectively). Finally, clinicians with AD-consistent CSF values 
reported the highest diagnostic confidence compared to clinicians with other types of CSF data. 
As such, AD-consistent CSF biomarkers may exert a confirmatory effect relative to more 
familiar, established clinical details with which clinicians currently have more experience.  
 Third, ambiguous CSF values had little effect on clinical decisions. Clinicians who 
viewed borderline CSF information made unknown etiology and AD-related diagnoses in 
relatively equal frequency, suggesting that CSF information had no effect on diagnosis for these 
participants. Moreover, the decision to initiate treatment was not significantly different between 
clinicians who viewed normal or borderline CSF values on the AD vignette, suggesting that 
values showing relatively increased risk for AD pathology (i.e., borderline CSF values) did not 
affect treatment planning. Current practice guidelines and diagnostic criteria for AD do not 
endorse use of CSF biomarkers in part because of the potential for indeterminate biomarker 
values (McKhann et al., 2011). Furthermore, Zetterberg and colleagues (2012) caution that 
clinicians may misinterpret CSF biomarker results as definitive, without considering the entire 
clinical picture. The results of this study suggest that when presented with ambiguous or 
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indeterminate CSF values, clinicians rely on other clinical details to make diagnostic and 
treatment decisions.  
 Fourth, inconsistent pathological and clinical information affects clinical decisions. 
Clinicians who viewed normal CSF values in a vignette that included other clinical details 
consistent with AD most often chose a diagnosis with unknown etiology. In contrast, clinicians 
who viewed AD-consistent CSF values in a vignette that included other ambiguous clinical 
details were swayed by those CSF values and made an AD-related diagnosis. In sum, clinicians 
appear to give less weight to CSF biomarkers when they are in the normal range, and greater 
weight when they are consistent with AD pathology, even when paired with ambiguous clinical 
details. Furthermore, on the borderline vignette, clinicians who had AD-consistent CSF 
information were 12 times more likely to make an AD-related diagnosis than clinicians who did 
not have CSF information. In contrast, the same comparison was relatively muted for the AD 
vignette, in part because clinicians who did not have CSF information made unknown etiology 
and AD-related diagnoses in equal numbers. In terms of treatment, CSF values affected the 
decision to initiate treatment in the borderline vignette, whereas this effect was questionable for 
the AD vignette. Taken together, in the setting of borderline clinical details, AD-consistent CSF 
values are likely to be more impactful on diagnosis and treatment planning, whereas the same 
values had less effect on clinical decisions in a mild AD case.  
These findings suggest that clinicians do not view CSF values in a vacuum, but consider 
their utility in combination with other clinical details to make decisions. Clinician reports on the 
use and the utility of clinical tools shed light on how evaluations are currently conducted, and 
how they might evolve as CSF testing becomes more widespread in clinical settings. Overall, 
reported use of neuropsychological screening and testing, neuroimaging, and lumbar puncture 
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were consistent with current practice guidelines for evaluating patients with memory complaints 
(McKhann et al., 2011). However, there were variations in ratings of use and utility of each tool 
and significant differences between practice specialties, suggesting the lack of standardization in 
dementia assessment. Neurologists report the greatest use and utility of cognitive assessments 
and neuroimaging. In contrast, nonspecialists in solo private practice or smaller clinics may rely 
more heavily on clinical history due to limited resources or specialized training. Heterogeneity in 
assessment techniques was also apparent in response to the vignettes. While a quarter of the 
sample agreed that neuropsychological testing, neuroimaging, and laboratory values would have 
been useful as part of the vignettes in forming a diagnosis, there were many infrequent 
responses. Only 16% of clinicians requested medical history or follow-up visit information, and 
only 6% mentioned the importance of exploring potentially reversible causes of dementia, all of 
which are recommended according to current practice guidelines (McKhann et al., 2011). Future 
studies might examine how clinicians assess CSF information in combination with additional 
common clinical measures or as part of potential future clinical practice criteria.  
 This study was the first, to our knowledge, to examine how clinicians use CSF 
information to diagnose dementia. A number of limitations, however, should be acknowledged. 
First, the vignettes were brief in order to encourage participation among busy clinicians and 
lacked the more extensive detail that some clinicians might have access to in practice. Future 
studies could include additional test results, such as neuropsychological test scores, MRI reports, 
and functional assessments, and examine how various combinations of results influence clinical 
decision-making. More extensive vignettes comprised of formal diagnostic criteria could allow 
for a more complete understanding of the function of CSF information within current practice 
guidelines. Furthermore, future studies could incorporate factors likely to be present in deciding 
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to order CSF testing, such as cost and patient willingness. Second, our sample disproportionately 
included physicians employed in academic medical centers, whose familiarity with CSF values 
may differ from clinicians in private practice. Therefore, although we obtained some 
heterogeneity in our sample, which also included non-physicians, the generalizability of our 
results may be limited. Third, we were not able to examine the effect of CSF values on specific 
diagnoses due to small cell sizes, nor did this study assess the utility of biomarkers in differential 
diagnosis across the dementias. Given that CSF biomarkers have been useful for differential 
diagnosis of dementia in research settings, it is important to understand how CSF information 
would influence decision-making for varied patient presentations.    
Despite these limitations, this study suggests that CSF values impact clinical decisions, 
even while clinicians do not view them as especially useful. CSF information is likely to become 
more widely used in clinical practice in the years ahead, particularly as clinicians attempt to 
identify preclinical cases for early intervention. This study represents a first step in exploring the 
potential role of CSF biomarkers in clinical evaluations, and in understanding how clinicians 
integrate clinical and pathological information to make clinical decisions. 
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Table 1  
 
Participant Characteristics (N =193) 
 
Characteristic  M/n SD/% 
Sex  
   Male 
   Female 
   Unspecified 
 
102 
84 
7 
 
53 
44 
4 
Age 50.98 10.80 
Race/Ethnicity 
   White 
   Asian 
   Hispanic, Latino, Spanish 
   Black or African American 
   Other 
 
153  
22 
6 
4  
8 
 
79 
11 
3 
2 
6 
Degree  
   MD 
   DO 
   NP 
   APRN 
   PA 
 
175 
7  
7 
2 
2  
 
90 
4 
4 
1 
1 
Practice specialty 
   Neurology 
   Geriatrics 
   Internal medicine 
   Primary care 
   Psychiatry 
   Unspecified 
 
93  
59  
15 
14  
10  
2  
 
48 
31 
8 
7 
5 
1 
Practice setting 
   University/Academic medical center 
   Veterans Administration Hospital 
   Clinic 
   Solo private practice 
   Hospital 
   Nursing home/Long term care 
   Unspecified 
 
147  
19  
13  
6  
3  
3 
2  
 
76 
10 
7 
3 
2 
2 
1 
Percentage of patients >65 years (%) 73.13 23.02 
Years in clinical practice 19.42  11.56 
Note. DO = Doctor of Osteopathic Medicine, NP = Nurse 
Practioner, APRN = Advanced Practice Registered Nurse,  
PA = Physician Assistant. 
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Table 2 
Frequency of Use and Utility of Diagnostic Tests (N = 193) 
 
Test  
 How often used 
M (SD) 
How useful 
 M (SD) 
Cognitive screening 
Comprehensive cognitive testing 
Structural neuroimaging 
Metabolic neuroimaging  
  4.59 (0.81) 
  3.17 (1.29) 
  3.87 (1.23) 
  1.64 (0.73) 
  4.10 (0.94) 
  4.00 (1.17) 
  3.24 (1.16) 
  2.45 (1.30) 
CSF analysis    1.56 (0.76)   2.16 (1.25) 
Note. All values are on a 1-5 Likert-type scale, 1 (Not at all), 3 (Moderately), 5 
(Very).  
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Table 3 
Diagnostic Confidence Ratings (N = 193) 
           Vignette 
 
CSF Condition 
Borderline 
M (SD) 
AD 
M (SD) 
CSF present 
CSF absent 
     3.40 (0.81) 
     3.16 (0.72) 
3.59b (0.79) 
3.24b (0.80) 
Normal CSF 
Borderline CSF 
AD CSF 
No CSF 
     3.28 (0.83) 
     3.25 (0.81) 
  3.67a (0.75) 
   3.16 a (0.72) 
     3.55 (0.78) 
     3.38c (0.72) 
     3.86d (0.80) 
   3.24cd (0.80) 
Note. “CSF present” encapsulates the three CSF conditions. All 
values are on a 1-5 Likert-type scale of diagnostic confidence, 1 
(Not at all), 3 (Moderately), 5 (Very).  
Values that share subscripts are significantly different at the p < 
.05 level. 
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Table 4 
 
Logistic Regression of Significant Predictors of Diagnostic Choice (AD Etiology versus 
Unknown Etiology) 
 
Predictor B SE B Exp(B) 95% C.I. Exp(B) 
Borderline vignette     
   Normal CSF group 
   Borderline CSF group 
-0.16       
   0.90 
0.54 
0.47 
  0.86 
  2.47 
    0.30 - 2.48   
    0.98 - 6.22 
   AD CSF group    2.50 0.51 12.21*** 4.50 - 33.17 
AD vignette     
   Normal CSF group 
   Borderline CSF group 
 -1.16 
 -0.10 
0.46 
0.43 
 0.31* 
 0.91 
     0.13 - 0.78   
     0.39 - 2.12 
   AD CSF group   1.53 0.54  4.60**  1.61 - 13.14 
   Post-vignette informant measure 1.16 0.29  3.17***      1.81 - 5.56 
Note. Nonsignificant predictors removed from logistic regression: Years in clinical practice, 
percentage of patients over the age of 65, practice specialty, vignette diagnostic confidence. 
*p < .05, ** p < .01, *** p < .001 
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Table 5 
Post-Vignette Ratings of Whether Clinical Information Increased or Decreased Diagnostic 
Confidence, Full Sample and by CSF Condition (N = 193) 
 
Clinical information 
     
Borderline vignette 
M (SD) 
AD vignette 
M (SD) 
Collateral report 
    Normal CSF 
    Borderline CSF 
    AD CSF 
    No CSF 
      4.16 (0.73) 
          4.23 (0.70) 
          4.18 (0.72) 
          4.26 (0.88) 
          4.02 (0.64) 
      4.28 (0.67) 
           4.22 (0.73) 
           4.20 (0.70) 
           4.56 c (0.55) 
           4.17 c (0.63) 
Functional status 
    Normal CSF 
    Borderline CSF 
    AD CSF 
    No CSF 
      4.02 (0.75) 
          4.11 (0.67) 
          4.07 (0.84) 
          4.14 (0.74) 
          3.83 (0.73) 
  4.10 (0.72) 
      4.11 (0.74) 
      4.14 (0.73) 
      4.16 (0.75) 
      4.02 (0.69) 
Patient age 
    Normal CSF 
    Borderline CSF 
    AD CSF 
    No CSF 
      3.54 (0.73) 
          3.36 b (0.79) 
          3.53 (0.69) 
          3.84 b (0.72) 
          3.48 (0.66) 
  3.52 (0.72) 
      3.35 d (0.67) 
      3.41e (0.72) 
      3.93 d,e,f (0.70) 
      3.43f (0.68) 
CSF informationa 
    Normal CSF 
    Borderline CSF 
    AD CSF 
      3.21 (0.93) 
          3.15 (0.91) 
          2.93g (0.72) 
          3.58g (1.03) 
  3.36 (0.98) 
      3.15h (1.01) 
      3.11i (0.78) 
      3.84hi (0.97) 
Note. Headings reflect values for entire sample; subheadings reflect values 
by CSF condition. All values are on a 1-5 Likert-type scale, 1 (Less 
confident), 3 (Neither less nor more confident), 5 (More confident).  
aThose who did not receive CSF information were not asked a follow-up 
question about it.  
Values that share subscripts are significantly different at the p < .05 level. 
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Figure 1. Randomization and procedural flow.  
 
 
 
 
 
 
 
 
 
 
 
Normal CSF CSF Education  
Borderline 
vignette 
AD vignette 
Borderline CSF CSF Education 
Borderline 
vignette  
AD vignette 
AD CSF CSF Education 
Borderline 
vignette 
AD vignette 
No CSF 
Borderline 
vignette 
AD vignette 
 26 
 
 
Figure 2. Percentage of clinicians choosing diagnostic categories by CSF condition for the 
borderline and AD vignettes. Adjusted standardized residuals, signifying difference from 
expected chi-square distribution, are significant at the ***p < .001 level. 
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Appendix A 
CSF education document 
Amyloid plaques and neurofibrillary tangles are the pathological hallmarks of 
Alzheimer’s disease (AD).  Amyloid beta peptide, most commonly the 42 amino acid form 
(Aβ42) is the major component of amyloid plaques; neurofibrillary tangles are made primarily of 
aggregated tau proteins, including tau phosphorylated at residue 181 (ptau181).  Aβ42, total tau 
protein and ptau181 can be detected in cerebrospinal fluid (CSF).  Many studies have shown that 
AD patients as a group have CSF with lower levels of Aβ42 and higher levels of tau and ptau181 
than cognitively normal people.  A ratio of tau/Aβ42 or ptau181/Aβ42 usually provides the best 
sensitivity and specificity to discriminate Alzheimer’s disease from cognitively normal, but there 
is overlap of values between groups.  This may be in large part because about 30% of cognitively 
normal people over the age of 65 have pathological and CSF changes typical of AD (Fagan et al., 
2007; Price and Morris, 1999; Price et al., 2009).  Several studies have shown that cognitively 
normal people whose CSF shows these changes are five-fold more likely than those without the 
changes to develop AD in the next 3-4 years (Fagan et al., 2007). Thus, changes in CSF (reduced 
levels of Aβ42 and increased levels of tau and ptau181) may be very specific for the brain 
pathology of AD but can be seen in people who do not have the symptoms of AD; these people 
are at higher risk of having AD in the future and may have “preclinical” or “presymptomatic” 
AD.  
Clinical testing for AD CSF biomarkers is available commercially from Athena 
Diagnostics. Athena provides values of Aβ42, tau and ptau181 without reference ranges and 
provides a normalized ratio of Aβ42 to total tau (called the AT index) and level of ptau to 
discriminate patients with Alzheimer’s disease from those with etiologies for cognitive change.  
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An AT index of less than 1.0 and P-tau concentration of > 61 pg/ml are suggestive of AD.  They 
note that there is some overlap between normal individuals and those with AD (e.g. AT index 
0.8-2.0 and ptau 54-68 pg/ml are in a “borderline” range).  Athena cites a sensitivity of 85-94% 
and a specificity of 83-90% for this ratio, citing two studies (Hulstaert et al., 1999; Andreasen et 
al., 2001).  
For reference, we also provide CSF biomarker values observed in research participants 
who had a clinical assessment at Washington University (Table 1) and values observed observed 
in a subset of these research participants who had autopsy proven AD.  
 
Table 1.  CSF Biomarker Values in Research Participants at the Knight ADRC Comparing 
Cognitively Normal Individuals (Clinical Dementia Rating (CDR) of 0) to Those Who Have Very 
Mild or Mild AD (CDR 0.5 or 1).   
 
 No AD (n=90) Mild AD (n=33) 
 Mean Standard 
deviation 
Mean Standard 
deviation 
Aβ42    567 207 434 211 
tau 342 175 565 302 
ptau181  62 26 86 45 
Note: All values shown are in pg/ml. The data were aggregated and did not allow calculation of 
ATI. 
 
Table 2.  CSF Biomarker Values in 29 Individuals with Autopsy Proven AD (unpublished data 
from the Knight ADRC) 
 
 Mean 
(Standard 
Deviation) 
MIN MAX MEDIAN 
Aβ42    425 (171) 183 786 360 
tau 574 (287) 156 1200 544 
ptau181 84 (38) 25 192 78 
ATI 0.54 (0.3) 0.12 1.58 0.52 
Note: All values shown are in pg/ml. 
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 Appendix B 
Borderline vignette 
A 73-year-old retired pilot comes to your office for routine follow-up with his son who 
lives nearby and sees him several times per week. His son reports he is concerned about his 
father’s memory. The son reports that his father has always been a little repetitious but now 
might tell the same story within a day. He is more dependent on his calendar to keep track of 
appointments, checking it several times per day. He might forget the details of some recent 
events, but recalls events well “if it interests him.” He still drives but has been reluctant to drive 
to his son’s new home. He still goes to church and plays golf with friends. He still does minor 
home repairs but they take him longer. He is independent in activities of daily living. The patient 
is not overly concerned about his memory, stating some things just aren't important to him 
anymore. The patient and his son both report his mood is low sometimes, but he denies having 
low mood most days for two weeks or more.   
AD vignette 
A 71-year-old retired real estate agent comes to your office. His wife is also your patient 
and while you are seeing her she mentions she has some concerns about her husband’s 
memory. She reports he has forgotten several appointments in the past year and often forgets 
things she has told him. He recalls recent events but is less likely to recall the details. He is still 
driving, but struggles to find less familiar places. He attends church but stopped serving as a 
deacon last year because he was having difficulty making decisions; he still meets with retired 
friends often. She noted that he takes longer to do home repairs and has taken several months to 
put up shelves in the garage and they are not up to his usual standard. He is independent in his 
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activities of daily living. The patient reports his wife is worried about his memory but that he has 
not noticed any changes. They both denied low mood.   
CSF values accompanying vignettes 
Normal CSF: Aβ42  = 750 pg/ml 
Total tau = 330 pg/ml 
ptau181  = 40 pg/ml 
ATI (Athena) =1.2 
Borderline CSF: Aβ42  = 502 pg/ml 
Total tau = 216 pg/ml 
ptau181  = 60 pg/ml 
ATI (Athena) = 1.0 
AD CSF: Aβ42  = 300 pg/ml 
Total tau = 619 pg/ml 
ptau181 = 86 pg/ml 
ATI (Athena) = 0.31 
 
